100
Participants
Start Date
August 19, 2020
Primary Completion Date
February 17, 2023
Study Completion Date
February 17, 2023
Nirsevimab
Single fixed IM dose of nirsevimab 50 mg if body weight \< 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
Research Site, Brussels
Research Site, Soweto
Research Site, Parktown
Research Site, Liège
Research Site, Barcelona
Research Site, Syracuse
Research Site, Granada
Research Site, Madrid
Research Site, Madrid
Research Site, North Charleston
Research Site, Tampa
Research Site, Memphis
Research Site, Dnipro
Research Site, Kharkiv
Research Site, Fort Worth
Research Site, Los Angeles
Research Site, Tacoma
Research Site, Bunkyō City
Research Site, Fuchu-shi
Research Site, Kawasaki-shi
Research Site, Kurume-shi
Research Site, Kyoto
Research Site, Nagasaki
Research Site, Setagaya-ku
Research Site, Tsukuba
Research Site, Yokohama
Research Site, Bydgoszcz
Research Site, Nottingham
Lead Sponsor
Iqvia Pty Ltd
INDUSTRY
AstraZeneca
INDUSTRY